Denis Thieffry

Denis Thieffry

Auto-generated profile, based on publicly available information

Denis Thieffry

Institut Curie, Université PSL, Paris, France

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2006 in Bioinformatics
Verified
Journal Article
Open access
AFAdrien Fauré
Adrien Fauré
ANAurélien Naldi
Aurélien Naldi
CCClaudine Chaouiya
Claudine Chaouiya
DTDenis Thieffry
Denis Thieffry
Motivation: To understand the behaviour of complex biological regulatory networks, a proper integration of molecular data into a full-fledge formal dynamical model is ultimately required. As most available data on regulatory interactions are qualitative, logical modelling offers an interesting framework to delineate the main dynamical properties of the underlying networks. Results: Transposing a generic model of the core network controlling the mammalian cell cycle into the logical framework, we compare different strategies to explore its dynamical properties. In particular, we assess the respective advantages and limits of synchronous versus asynchronous updating assumptions to delineate the asymptotical behaviour of regulatory networks. Furthermore, we propose several intermediate strategies to optimize the computation of asymptotical properties depending on available knowledge. Availability: The mammalian cell cycle model is available in a dedicated XML format (GINML) on our website, along with our logical simulation software GINsim (). Higher resolution state transitions graphs are also found on this web site (Model Repository page). Contact: thieffry@ibdm.univ-mrs.fr


26 November 2004 in Genome Biology
Verified
Journal Article
Open access
DMDavid Martin
David Martin
CBChristine Brun
Christine Brun
ERElisabeth Remy
Elisabeth Remy
PMPierre Mouren
Pierre Mouren
DTDenis Thieffry
Denis Thieffry
BJBernard Jacq
Bernard Jacq
We have developed methods and tools based on the Gene Ontology (GO) resource allowing the identification of statistically over- or under-represented terms in a gene dataset; the clustering of functionally related genes within a set; and the retrieval of genes sharing annotations with a query gene. GO annotations can also be constrained to a slim hierarchy or a given level of the ontology. The source codes are available upon request, and distributed under the GPL license.

27 June 2011 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MTMorgane Thomas-Chollier
Morgane Thomas-Chollier
MDMatthieu Defrance
Matthieu Defrance
AMAlejandra Medina-Rivera
Alejandra Medina-Rivera
OSOlivier Sand
Olivier Sand
CHCarl Herrmann
Carl Herrmann
JHJacques van Helden
Jacques van Helden
RSAT (Regulatory Sequence Analysis Tools) comprises a wide collection of modular tools for the detection of cis -regulatory elements in genome sequences. Thirteen new programs have been added to the 30 described in the 2008 NAR Web Software Issue, including an automated sequence retrieval from EnsEMBL ( retrieve-ensembl-seq) , two novel motif discovery algorithms ( oligo-diff and info-gibbs ), a 100-times faster version of matrix-scan enabling the scanning of genome-scale sequence sets, and a series of facilities for random model generation and statistical evaluation ( random-genome-fragments, random-motifs, random-sites, implant-sites, sequence-probability, permute-matrix ). Our most recent work also focused on motif comparison ( compare-matrices ) and evaluation of motif quality ( matrix-quality ) by combining theoretical and empirical measures to assess the predictive capability of position-specific scoring matrices. To process large collections of peak sequences obtained from ChIP-seq or related technologies, RSAT provides a new program ( peak-motifs) that combines several efficient motif discovery algorithms to predict transcription factor binding motifs, match them against motif databases and predict their binding sites. Availability (web site, stand-alone programs and SOAP/WSDL (Simple Object Access Protocol/Web Services Description Language) web services): http://rsat.ulb.ac.be/rsat/ .

1 August 2020 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
SKSarah M Keating
Sarah M Keating
DWDagmar Waltemath
Dagmar Waltemath
Matthias KönigMatthias König
Matthias König
FZFengkai Zhang
Fengkai Zhang
Andreas DrägerAndreas Dräger
Andreas Dräger
MHMichael Hucka
Michael Hucka
Systems biology has experienced dramatic growth in the number, size, and complexity of computational models. To reproduce simulation results and reuse models, researchers must exchange unambiguous model descriptions. We review the latest edition of the Systems Biology Markup Language (SBML), a format designed for this purpose. A community of modelers and software authors developed SBML Level 3 over the past decade. Its modular form consists of a core suited to representing reaction‐based models and packages that extend the core with features suited to other model types including constraint‐based models, reaction‐diffusion models, logical network models, and rule‐based models. The format leverages two decades of SBML and a rich software ecosystem that transformed how systems biologists build and interact with models. More recently, the rise of multiscale models of whole cells and organs, and new data sources such as single‐cell measurements and live imaging, has precipitated new ways of integrating data with models. We provide our perspectives on the challenges presented by these developments and how SBML Level 3 provides the foundation needed to support this evolution.

1 January 2009 in BMC Systems Biology
Verified
Journal Article
Open access
PDF file
Ozgur SahinOzgur Sahin
Ozgur Sahin
Holger FröhlichHolger Fröhlich
Holger Fröhlich
CLChristian Löbke
Christian Löbke
UKUlrike Korf
Ulrike Korf
SBSara Burmester
Sara Burmester
DADorit Arlt
Dorit Arlt
In breast cancer, overexpression of the transmembrane tyrosine kinase ERBB2 is an adverse prognostic marker, and occurs in almost 30% of the patients. For therapeutic intervention, ERBB2 is targeted by monoclonal antibody trastuzumab in adjuvant settings; however, de novo resistance to this antibody is still a serious issue, requiring the identification of additional targets to overcome resistance. In this study, we have combined computational simulations, experimental testing of simulation results, and finally reverse engineering of a protein interaction network to define potential therapeutic strategies for de novo trastuzumab resistant breast cancer. First, we employed Boolean logic to model regulatory interactions and simulated single and multiple protein loss-of-functions. Then, our simulation results were tested experimentally by producing single and double knockdowns of the network components and measuring their effects on G1/S transition during cell cycle progression. Combinatorial targeting of ERBB2 and EGFR did not affect the response to trastuzumab in de novo resistant cells, which might be due to decoupling of receptor activation and cell cycle progression. Furthermore, examination of c-MYC in resistant as well as in sensitive cell lines, using a specific chemical inhibitor of c-MYC (alone or in combination with trastuzumab), demonstrated that both trastuzumab sensitive and resistant cells responded to c-MYC perturbation. In this study, we connected ERBB signaling with G1/S transition of the cell cycle via two major cell signaling pathways and two key transcription factors, to model an interaction network that allows for the identification of novel targets in the treatment of trastuzumab resistant breast cancer. Applying this new strategy, we found that, in contrast to trastuzumab sensitive breast cancer cells, combinatorial targeting of ERBB receptors or of key signaling intermediates does not have potential for treatment of de novo trastuzumab resistant cells. Instead, c-MYC was identified as a novel potential target protein in breast cancer cells.